scispace - formally typeset
B

Brian P. Doehle

Researcher at University of Washington

Publications -  56
Citations -  5758

Brian P. Doehle is an academic researcher from University of Washington. The author has contributed to research in topics: Sofosbuvir & Ledipasvir. The author has an hindex of 34, co-authored 56 publications receiving 5394 citations. Previous affiliations of Brian P. Doehle include Harvard University & Washington University in St. Louis.

Papers
More filters
Journal ArticleDOI

Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis

TL;DR: Treatment with sofosbuvir-velpatasvir with or without ribavirin for 12 weeks and with so-called "superdrugs" for 24 weeks resulted in high rates of sustained virologic response in patients with HCV infection and decompensated cirrhosis.
Journal ArticleDOI

A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV‐1 and HIV‐2 Vif proteins

TL;DR: It is argued that HIV‐1 Vif has evolved to suppress at least two distinct but related human antiretroviral DNA‐editing enzymes.
Journal ArticleDOI

IL-1β Production through the NLRP3 Inflammasome by Hepatic Macrophages Links Hepatitis C Virus Infection with Liver Inflammation and Disease

TL;DR: RNA sequencing analysis comparing THP1 cells and chronic hepatitis C patient liver demonstrates that viral engagement of the NLRP3 inflammasome stimulates IL-1β production to drive proinflammatory cytokine, chemokine, and immune-regulatory gene expression networks linked with HCV disease severity.
Journal ArticleDOI

Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels

TL;DR: Results support that Cbfa1 is a key regulatory factor in the vascular calcification observed in dialysis patients and is up-regulated in response to many uremic toxins.
Journal ArticleDOI

A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor

TL;DR: It is demonstrated that a single APOBEC3G residue controls the ability of the HIV-1 Vif protein to bind and inactivate these host defense factors, suggesting the biological barrier preventing the entry of additional SIV into the human population as zoonotic infections is potentially quite fragile.